Table 5.
Cetuximab response in 14 wild-type KRAS, NRAS and BRAF mCRC patients with/without PIK3CA exon 9 mutations.
| Patient | Age | Gender | PIK3CA exon 9 mutation | Tumor location | Tumor differentiation | Before or after resection | Courses of cetuximab | PFS (m) | Clinical response |
|---|---|---|---|---|---|---|---|---|---|
| A | 60 | Female | E545K | Right colon | Medium | Before | 9 | 5.3 | SD |
| B | 50 | Female | E545K | Left colon | Poor | Before | 17 | 12.2 | SD |
| C | 52 | Male | E542K | Left colon | Moderate | After | 5 | 2.3 | SD |
| D | 64 | Male | E542K | Left colon | Moderate | After | 3 | 1.3 | PR |
| E | 63 | Male | E542K | Left colon | Moderate | After | 4 | 1.5 | SD |
| F | 53 | Male | Wild-type | Left colon | Moderate | After | 16 | 9.4 | SD |
| G | 32 | Male | Wild-type | Left colon | Moderate | Before | 2 | 1.3 | SD |
| H | 70 | Male | Wild-type | Left colon | Moderate | Before | 8 | 3.5 | SD |
| I | 39 | Male | Wild-type | Left colon | Well | Before | 7 | 3.0 | PR |
| J | 57 | Male | Wild-type | Left colon | Moderate | After | 3 | 1.2 | SD |
| K | 53 | Female | Wild-type | Left colon | Well | Before | 8 | 5.6 | SD |
| L | 45 | Male | Wild-type | Left colon | Moderate | Before | 8 | 3.6 | SD |
| M | 53 | Male | Wild-type | Left colon | Moderate | After | 3 | 2.0 | PD |
| N | 62 | Male | Wild-type | Left colon | Poor | After | 11 | 7.1 | SD |
PFS, progression-free survival; SD, stable disease; PR, partial response; PD, progressive disease.